CAM
RIGL icon

Cormorant Asset Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Cormorant Asset Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-153,975
Closed -$4.2M – 62
2017
Q2 		$4.2M Sell
153,975
-46,025
-23% -$1.26M 0.7% 40
2017
Q1 		$6.62M Sell
200,000
-86,870
-30% -$2.21M 0.96% 34
2016
Q4 		$6.83M Buy
286,870
+171,310
+148% +$4.91M 0.92% 34
2016
Q3 		$4.24M Buy
+115,560
New +$3.31M 0.47% 55

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cormorant Asset Management's RIGL Position: Q3 2017 in Review

Cormorant Asset Management sold out of Rigel Pharmaceuticals (RIGL) in Q3 2017, closing a stake of 153,975 shares — an estimated $4.2M sold.

Cormorant Asset Management first reported a position in RIGL in Q3 2016 and held it in 4 quarters. The position peaked at $6.83M in Q4 2016. 108 funds tracked by Wall St. Rank hold RIGL as of Q3 2017.

  • Cormorant Asset Management reported no remaining Rigel Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Cormorant Asset Management sold 153,975 Rigel Pharmaceuticals shares in Q3 2017, an estimated $4.2M.
  • Cormorant Asset Management first reported a position in Rigel Pharmaceuticals in Q3 2016 and held it in 4 quarters.
  • Cormorant Asset Management's Rigel Pharmaceuticals position peaked at $6.83M in Q4 2016.
  • 108 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2017.

Based on Cormorant Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.